Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial-Reference-Cited by-同舟云学术

Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial

Published:2012-03-14 Issue:4 Volume:166 Page:853-860
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:

Author:

Bissonnette R.,Poulin Y.,Zhou Y.,Tan J.,Hong H.C.,Webster J.,Ip W.,Tang L.,Lyle M.

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2133.2011.10775.x/fullpdf

Reference15 articles.

1. Future perspectives in the treatment of atopic dermatitis;Katoh;J Dermatol,2009

2. Atopic dermatitis;Bieber;N Engl J Med,2008

3. New insights into atopic dermatitis;Leung;J Clin Invest,2004

4. A review of atopic dermatitis;Wise;Compr Ther,2006

5. Treatment of recalcitrant atopic dermatitis with omalizumab;Lane;J Am Acad Dermatol,2006

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Topical anti-inflammatory treatments for eczema: network meta-analysis;Cochrane Database of Systematic Reviews;2024-08-06

2. Topical Treatments in Atopic Dermatitis: An Expansive Review;Journal of Clinical Medicine;2024-04-10

3. Efficacy and safety of Ruxolitinib, Crisaborole, and Tapinarof for mild-to-moderate atopic dermatitis: a Bayesian network analysis of RCTs;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-02-15

4. Aryl hydrocarbon receptor and IL-13 signaling crosstalk in human keratinocytes and atopic dermatitis;Frontiers in Allergy;2024-01-26

5. Tapinarof, a Novel Topical Therapeutic Aryl Hydrocarbon Receptor Agonist, Suppresses Atopic Dermatitis-like Skin Inflammation in Mice;BPB Reports;2024